Related references
Note: Only part of the references are listed.Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy
Miren Zuazo et al.
EMBO MOLECULAR MEDICINE (2019)
Cancer Neoantigens
Ton N. Schumacher et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 37, 2019 (2019)
Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity
Kenji Chamoto et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Follicular CXCR5-expressing CD8+ T cells curtail chronic viral infection
Ran He et al.
NATURE (2016)
Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy
Se Jin Im et al.
NATURE (2016)
CXCR5+ follicular cytotoxic T cells control viral infection in B cell follicles
Yew Ann Leong et al.
NATURE IMMUNOLOGY (2016)
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
Vassiliki A. Boussiotis
NEW ENGLAND JOURNAL OF MEDICINE (2016)
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
Weiping Zou et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
PD-1 Blockade Expands Intratumoral Memory T Cells
Antoni Ribas et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Interaction of Both SH2 Domains of SHP-2 with a PD-1 Homodimer Is Required for PD-1-Mediated Inhibition of T Cell Responses
Nikolaos Patsoukis et al.
BLOOD (2016)
Immunotherapy: The Path to Win the War on Cancer?
CELL (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
Janis M. Taube et al.
CLINICAL CANCER RESEARCH (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody
Evan J. Lipson et al.
CLINICAL CANCER RESEARCH (2013)
Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2
Tadashi Yokosuka et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Phenotype, Function, and Gene Expression Profiles of Programmed Death-1hi CD8 T Cells in Healthy Human Adults
Jaikumar Duraiswamy et al.
JOURNAL OF IMMUNOLOGY (2011)
The PD-1 pathway in tolerance and autoimmunity
Loise M. Francisco et al.
IMMUNOLOGICAL REVIEWS (2010)
B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells
Takeshi Azuma et al.
BLOOD (2008)
Cutting edge:: Programed death (PD) ligand-1/PD-1 interaction is required for CD8+ T cell tolerance to tissue antigens
Natalia Martin-Orozco et al.
JOURNAL OF IMMUNOLOGY (2006)
PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection
Constantinos Petrovas et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
Cheryl L. Day et al.
NATURE (2006)
Restoring function in exhausted CD8 T cells during chronic viral infection
DL Barber et al.
NATURE (2006)
PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3ζ signalosome and downstream signaling to PKCθ
KA Sheppard et al.
FEBS LETTERS (2004)
SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation
JM Chemnitz et al.
JOURNAL OF IMMUNOLOGY (2004)
The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice
MJI Ansari et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis
AD Salama et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans
L Prokunina et al.
NATURE GENETICS (2002)
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
HD Dong et al.
NATURE MEDICINE (2002)
PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine
T Okazaki et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
PD-L2 is a second ligand for PD-I and inhibits T cell activation
Y Latchman et al.
NATURE IMMUNOLOGY (2001)
Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice
H Nishimura et al.
SCIENCE (2001)
Share Paper
